Development status: Approved, off-patent

Gram-positive activity

Mechanism of Action/Target pathogen: Binds to the rRNA of the bacterial 50S ribosome subunit, overlapping with the binding sites of the oxazolidinone, pleuromutilin, and macrolide antibiotics, thus blocking ribosomal translocation. Bacteriostatic activity against Gram-positive bacteria including many MRSA strains.

Additional information: Semisynthetic lincosamide derived from lincomycin. Oral and parenteral application. Alternative treatment of protozoal diseases and anaerobic bacterial infections.